S everal therapies [1] [2] [3] [4] [5] have already been proposed to treat cerebral cavernous malformations (CCMs), a disease that often leads to hemorrhagic stroke and seizures. These have largely arisen from the study of impact of downregulation of CCM genes on cultured endothelial cells. A recent study 6 demonstrated that treatments targeting Rho or the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) proteases may be more efficacious in treating CCM disease than other therapies. In a previous report, 2 using a limited number of animals, we showed that the Rho kinase (ROCK) inhibitor, Fasudil, decreased CCM lesion burden in a heterozygous murine model where lesions develop stochastically during life, with all phenotypic signatures recapitulating the human disease. 7 We now aimed to replicate our previous results with Fasudil, using a larger cohort of animals with 2 heterozygous Ccm genotypes. We also treated the murine models with simvastatin, commonly used in humans, with weak ROCK inhibitor properties. [8] [9] [10] [11] Unlike specific ROCK inhibitors, statins have broader pleiotropic effects, 8 and concerns have been raised whether they might increase brain hemorrhage. [12] [13] [14] Hence, besides assessing the effect of treatment on the number, stage, and size of CCM lesions in each animal brain, we also Background and Purpose-We sought to compare the effect of chronic treatment with commonly tolerated doses of Fasudil, a specific RhoA kinase (ROCK) inhibitor, and simvastatin (with pleiotropic effects including ROCK inhibition) on cerebral cavernous malformation (CCM) genesis and maturation in 2 models that recapitulate the human disease. Methods-Two heterozygous murine models, Ccm1
Msh2
−/− and Ccm2
, were treated from weaning to 4 to 5 months of age with Fasudil (100 mg/kg per day), simvastatin (40 mg/kg per day) or with placebo. Mouse brains were blindly assessed for CCM lesion burden, nonheme iron deposition (as a quantitative measure of chronic lesional hemorrhage), and ROCK activity. Results-Fasudil, but not simvastatin, significantly decreased mature CCM lesion burden in Ccm1
−/− mice, and in meta-analysis of both models combined, when compared with mice receiving placebo. Fasudil and simvastatin both significantly decreased the integrated iron density per mature lesion area in Ccm1
−/− mice, and in both models combined, compared with mice given placebo. ROCK activity in mature lesions of Ccm1 
Trp53
−/− murine models for CCM disease were developed as previously reported. 7, 16 Based on previously demonstrated Knudsonian 2-hit mechanism (heterozygosity in the germ-line and biallelic somatic mutations in lesions), these models create Ccm heterozygous mice in p53-or Msh2-deficient backgrounds, predisposing to somatic mutations and enhancing CCM lesion genesis. 7, 16, 17 Immediately after weaning (P21), mice were randomly assigned to the respective treatment groups. One hundred forty-two Ccm1
Msh2
−/− mice (71 males and 71 females) and 72 Ccm2 +/− Trp53 −/− mice (61 males and 11 females) were included in the experiments. The breeding program for creating mice with the appropriate genotype has been described previously. 7, 16, 17 This is detailed along with a treatment assignment scheme in the Methods and Figure I in the onlineonly Data Supplement.
Randomized Assignment and Treatment Groups
For all groups, the National Institute of Neurological Disorders and Stroke guidelines for objectivity in preclinical research were followed including randomization, blinding of outcome assessment, appropriate sample-size estimation based on the primary outcome, and prespecified data analyses. 18 Ccm1
Msh2
−/− mice were randomized at weaning to receive Fasudil (100 mg/kg per day in the drinking water) or placebo with drug-free drinking water until 4 to 5 months of age. In a separate study, mice were randomized to receive simvastatin (40 mg/kg per day in the chow) or placebo controls with the same drug free-diet from weaning to 4 to 5 months of age. Ccm2
Trp53
−/− mice similarly assigned to receive the same regimen of Fasudil or placebo and simvastatin or placebo. Late, short-term studies were completed for Ccm1
Msh2
−/− treated for a 1-month duration, from 3 to 4 months of age, with Fasudil (100 mg/kg per day in the drinking water) or placebo. A concurrent randomly assigned cohort (15 mice) of the Ccm1
−/− models were used as placebos for the long-term studies with simvastatin and for the late, short-term studies with Fasudil. Notably, the body weights of the CCM models were not affected by Fasudil or simvastatin treatment (Table I in the online-only Data Supplement).
CCM Lesion Analysis
After treatment, brains were removed and assessed for lesion burden on serial histological sections by a procedure previously described. 2, 7 Briefly, formalin-fixed brains were cut into 1-mm-thick coronal slices, placed into cassettes, and processed. After embedding the slices in paraffin, the slices were cut into 5-µm-thick sections with a microtome. After staining with hematoxylin and eosin, the sections were assessed for the number of stage 1 prelesions (single ballooned capillaries >100 μm in diameter) and stage 2 lesions (mature, multicavernous) by 2 observers (R.S. and C.S., C.A., or T.M.), with adjudication by a third observer (I.A.A.), as was done previously. 2, 7, [19] [20] [21] All assessors were blinded to the treatment assignment. The lesional area was determined by using the polygon area function of a microscope digital camera DP21 (Olympus) as described previously. 19 Hematoxylin and eosin-stained sections from brains of mice that either died or euthanized because of a debilitating illness were examined for hemorrhage or tumors (Table II in the online-only Data Supplement). Tumors on sections were confirmed by University of Chicago neuropathologist P.P.
Blank sections from brains with stage 2 CCM lesions were processed for quantitative assessment of nonheme iron deposition by Perls Prussian blue and for ROCK activity by the intensity of phosphorylated myosin light chain through methods previously described. 2, 7, 19 We had previously shown that stage 1 prelesions do not manifest iron deposition, 7 and this was also true in the present study. Figure 1 illustrates typical stage 1 and 2 lesions and associated iron depiction in the latter.
Primary and secondary outcomes are defined, and the statistical methods are presented in the Methods in the online-only Data Supplement.
Results

Fasudil, but Not Simvastatin, Decreases Lesion Burden in CCM Models
The 
Trp53
−/− animals ( Figure 2B ). There were significant increases in stage 1 lesion counts, and no impact on total lesion counts, as the proportion of stage 2 lesions among total lesions decreased from 65% in placebos to 22% in the Fasudil-treated Ccm1
Msh2
−/− mice (P=0.02) and decreased from 64% in placebos to 21% in the Fasudil-treated Ccm2
−/− murine model (P=0.002), indicating an effect of treatment on lesion maturation.
In contrast, the number of stage 2 lesions per mouse and other lesion counts were not decreased by simvastatin in either of the genotypes compared with placebo. A metaanalysis of combined effect in the 2 genotypes showed a significantly decreased incidence of stage 2 lesions favoring Fasudil (P=0.017; Figure 2C ). A similar meta-analysis showed no significant effect of simvastatin on the incidence of stage 2 lesions in the 2 genotypes ( Figure 2D ). Neither Fasudil nor simvastatin significantly affected lesional crosssectional area in either genotype. But there was a trend of a smaller stage 2 lesional area in Fasudil-treated mice, A few significant observations arose in the prespecified subgroup analysis of results per the animal's sex (Table III in 
Trp53
−/− females, there were significantly fewer total (stage 1 and 2) lesions/animal in simvastatin-treated mice than in placebos (P=0.02), an effect not present in the cohort as a whole. But we did note an imbalance in treatment assignment between sexes.
Fasudil given later in life for 1 month (at age 3-4 months) to Ccm1
−/− mice did not affect lesion burden when compared with placebo in the overall treated cohort ( Figure III in the online-only Data Supplement). However, in male mice, the total number of lesions per mouse was significantly lower, 2.89±0.93 in 9 placebos versus 1.29±0.68 in 7 Fasudil-treated animals (P=0.036). An opposite effect (greater lesion burden) was observed in female mice, but did not reach statistical significance. There was an imbalance in the placebo group, with females harboring fewer lesions. 
Msh2
−/− murine model. B, Neither F (n=18 P, n=18 F-treated mice) nor S (n=11 P, n=12 S-treated mice), significantly affected lesion burden in Ccm2
−/− mice. Metaanalysis of combined effect in the 2 models showed that incidence of stage 2 lesions is decreased with F (C), but not with S (D). The DerSimonian and Laird method 22 used for the meta-analyses considers the relative contribution of effect by the 2 models (weight %) and their different penetrance (incidence rate ratio). CCM indicates cerebral cavernous malformation; and CI, confidence interval. 
Trp53
−/− murine model, when compared with placebo-treated animals. Meta-analyses of effect on nonheme iron density per stage 2 lesional area in the 2 genotypes favored both Fasudil and simvastatin over placebo (P=0.017 and P<0.001, respectively). There was no differential sex effect of either treatment on iron deposit in lesions (Table IV in 
−/− murine model. Meta-analysis of combined effect in the 2 models showed that nonheme iron deposition per lesion area in stage 2 lesions is decreased with Fasudil (C) and with simvastatin (D). The DerSimonian and Laird method 22 used for the meta-analyses considers the relative contribution of effect by the 2 models (weight %) and their difference in iron deposition per lesion. CCM indicates cerebral cavernous malformation; and CI, confidence interval.
significantly decreased from 68.7% in placebos to 51.9% in Fasudil-treated mice (P=0.01 versus placebo) and 57.0% in simvastatin-treated mice (P=0.007 versus placebo). There was no significant difference of percent endothelial cell immunopositivity among individual lesions or mice in the placebo, Fasudil, or simvastatin cohorts ( Figure IV in the online-only Data Supplement).
Fasudil Increases Survival in Ccm1 Models
The proportion of Ccm1
Msh2
−/− mice that survived to complete the long-term treatment was higher (P=0.05) with Fasudil than with placebo ( Figure 4 ). No significant difference on survival was observed between females and male animals. There was no effect on survival in this model with simvastatin treatment compared with placebos. For the Ccm2
murine model, no effect on survival was observed with either Fasudil or simvastatin treatment compared with placebos. In the Ccm1
−/− murine model treated from 3 to 4 months, there was a nonsignificant trend for increased survival with Fasudil treatment (17/18) compared with placebos (16/20) . No increase in brain hemorrhage in association with animal attrition was observed with either Fasudil or simvastatin treatment compared with placebos in either genotype (Table I in the online-only Data Supplement).
Discussion
Two classes of murine models of CCM disease are available to test potential experimental therapies. Acute models with postnatal-induced homozygous Ccm loss have been used to investigate mechanisms of CCM pathogenesis, including endothelial mesenchymal transition, 3 sulindac therapy, 4 δ-notch signaling, 5 and MEKK3-KLF2/4 (MAP [mitogen-activated protein]/ ERK [extracellular signal-regulated kinase] kinase kinase 3 -Krüppel-like factor 2/4) signaling. 6 These models result in high lesion burden in the developing hindbrain and retina, and animal attrition before the first month of age. Although allowing examination of signaling mechanisms involved in lesion genesis, these models assess neither CCM lesion maturation during life nor the hemorrhage burden from lesions, cardinal features of the human disease. In contrast, the chronic heterozygous models we used herein 7, 16, 17, 20 develop CCM lesions during the animal's lifespan, resembling the human disease more closely than the shorter lived acute models.
Our results provide evidence that long-term Fasudil treatment, but not simvastatin, prevents the development of mature, multicavernous CCM lesions. We also noted that both drugs are more efficacious in the Ccm1
Msh2
−/− compared with the Ccm2
−/− murine model. Meta-analysis of results from both genotypes confirmed a beneficial effect on the development of mature CCM lesions, favoring Fasudil treatment, but not simvastatin, over placebo. Although both drugs at the chosen doses seemed to affect endothelial ROCK activity similarly in mature murine lesions, there is evidence that statins result in weaker systemic ROCK inhibition when compared with specific ROCK inhibitor drugs, 9 and this could explain the differential benefit favoring Fasudil.
Fasudil and simvastatin both significantly decreased nonheme iron deposition in mature CCM lesions in 2 murine models. This effect was present even when adjusting for lesion area and occurred with simvastatin in the absence of reduction in lesion burden. Simvastatin effect on lesional iron deposition was even greater than Fasudil in the Ccm2
−/− mice. Previous studies 20, 23, 24 indicated that ROCK inhibition blocks endothelial hyperpermeability and actin stress fibers resulting from the heterozygous loss of CCM genes, both in cultured endothelial cells in vitro and in murine models in vivo, and simvastatin reverses dermal hyperpermeability in one of these models. 25 Our group had previously demonstrated a correlation of quantitative vascular permeability with iron content in human CCM lesions evaluated by advanced magnetic resonance imaging 
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techniques. 26 Blood leak from CCM lesions produces the most debilitating features of CCM disease, including hemorrhagic stroke and seizures. A favorable effect of either drug on lesional iron deposit is hence relevant clinically.
Long-term (≥ 4 months) experiments in rodents treated with Fasudil in the drinking water or by gavage have used doses ranging from 10 to 228 mg/kg per day without any reported attrition or complications. [27] [28] [29] [30] [31] [32] In our proposed experiments, we used the midrange dose of 100 mg/kg per day, already shown to reduce CCM lesion burden in pilot studies. 2 A lower dose of 10 mg/kg per day has been reported to be effective in suppressing cardiac allograft vasculopathy in mice. 27 An effect at a lower dose was not investigated herein, but would be particularly encouraging for translating this therapy to humans, where oral doses as high as 240 mg/d have been well tolerated in trials on angina, 33 and an intravenous dose of 90 mg/d is approved and has long been used in Japan for the prevention of cerebral vasospasm after subarachnoid hemorrhage. 34 Although treatment of transgenic mice indicates a potential therapeutic efficacy in CCM, Fasudil is a Rock1 and Rock2 inhibitor that was first approved in Japan in 1995 by Asahi Kasei Pharma Corporation for the treatment of cerebral vasospasm, and it has never been approved in the United States. Reported toxicity with Fasudil includes subcutaneous hemorrhage, subarachnoid hemorrhage, nausea, pyrexia, kidney failure, and hypotension. Long-term safety of Fasudil has not been assessed, in particular with concerns about hypotension and systemic side effects. Rock1 has widespread tissue distribution, but there is relatively little Rock1 in brain and skeletal muscle. Rock2 is mainly expressed in the central nervous system and is relatively low in liver, stomach, spleen, kidney, and testis (BioAxone US patent 7572913). Inhibitors that target Rock2 are currently being developed and would be expected to have much less systemic toxicity than inhibitors that target both kinases. For treatment of CCM, Rock2 inhibition promises to target cerebral microvessels and CCM vessels more selectively and could increase targeted effectiveness and minimize systemic side effect.
We have chosen simvastatin as our statin test agent because this drug was shown to reverse dermal hyperpermeability in Ccm heterozygous mice. 25 Simvastatin has been administered orally in the animals' chow, drinking water, or by gavage in doses ranging from 2 to 100 mg/kg per day in chronic (≥4 months) studies without adverse effects. [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] The target dose of simvastatin of 40 mg/kg per day is at the midrange used by other investigators and is thought to be equivalent to adult human doses of 20 to 40 mg/d widely used for cardiovascular-and cholesterol-lowering effects. 48 We should nevertheless be cautious about statin dose-effect, as statins have been reported to exhibit biphasic dose effects on inflammationinduced angiogenesis 49 and higher doses are typically needed to achieve greater ROCK inhibition pleiotropic effect. 9 Because simvastatin at 40 mg/kg per day in the chow was less effective in reducing lesion burden than Fasudil, we are currently treating the Ccm1
Msh2
−/− murine model with atorvastatin at 80 mg/kg per day in the chow (equivalent to simvastatin at 160 mg/kg per day in mice and thought to be equivalent to the high-dose atorvastatin 80 mg/d approved for clinical use in humans). A putative benefit on lesion burden and blunting CCM hemorrhage with higher dose statin will have implications on dose escalation in clinical trials that may be planned in humans. We are also in the process of treating Ccm3 +/− murine models with Fasudil, simvastatin, and atorvastatin, to determine whether ROCK inhibitors can reduce lesion burden in another model with a more penetrant genotype. 20 The benefit of Fasudil on lesion burden in the current study primarily impacted the development of mature multicavernous stage 2 lesions. Only stage 2 lesions have been associated with bleeding and inflammatory cell infiltrate in previous studies, 7 and we also noted no hemorrhage in stage 1 lesions in our current experiments. There was no effect on total lesion counts, and in fact we noted increases in stage 1 prelesion counts, and a greater prevalence of stage 1 lesions among total lesions. These results are all consistent with a therapeutic effect blunting lesion maturation into clinically relevant multicavernous phenotype, rather than lesion genesis. A trend was also noted of Fasudil on cross-sectional area of mature stage 2 lesions, as assessed by histological morphometry. The combined effect of therapy on lesional count and cross-sectional area promises to be more easily and accurately assessed in ongoing experiments using novel microcomputed tomographic technique recently introduced and validated by our team, with volumetric quantification of CCM lesion burden in murine brains. 50 We cannot comment on the relative benefits of ROCK inhibition versus B-cell depletion therapy, also demonstrated to be effective in chronic heterozygous Ccm murine models. 19 Either therapy may have a role in the clinical setting, and it is possible that ROCK inhibition effect is in part mediated by modulation of the immune response in lesions. Indeed, we had previously shown that ROCK inhibition decreases B-cell infiltration in murine CCM lesions, 2 and B-cell depletion decreases ROCK activity in lesional endothelium. 19 Other compelling therapeutic targets have been identified in CCM, based on aberrant signaling in conjunction with acute postnatally induced Ccm homozygocity. 3, 4, 6, 51 These therapeutic strategies have not been examined in chronic heterozygous models, and a recently identified primary CCM signaling effector was shown to act via downstream RhoA/ROCK activation. 6 Because of the small numbers of animals, imbalance of treatment assignment and different phenotype severity by sex, definitive conclusions cannot be determined from subgroup analyses by sex. Nevertheless, we documented a greater benefit of Fasudil on lesion burden in males in both short-term and long-term treatments, a potential negative effect of shortterm Fasudil treatment, and a weaker phenotype in female mice receiving placebo. These may reflect mechanistic biological effects and will need to be confirmed in future studies. A weaker effect of Fasudil on lesion development in Ccm2
Trp53
−/− mice, and a greater benefit of simvastatin than of Fasudil on lesional iron in this model, may also represent differential biological mechanisms. If these observations are confirmed in future studies, they may indicate a complex biology of ROCK inhibition requiring careful calibration.
Our experiments do not exclude pleiotropic effects of either drug, other than ROCK inhibition, as the mechanism of therapeutic effect. Animal weights were not affected by treatment in any cohort. And although we did not document blood pressure measurements, similar dose and duration of Fasudil treatment in mice did not significantly impact blood pressure in other studies. 30, 52 Duration of therapy in mice cannot be easily translated into a prescribed course of treatment in humans. Beyond doseeffect questions, it is unclear when or how long to administer the treatment to blunt lesion development and maturation. Clinical trials of ROCK inhibition with specific drugs and or statins may target lesion formation and progression to larger clinically more relevant lesions. CCM hemorrhage is the most compelling outcome parameter, associated with neurological sequelae, 53 and for the first time this report identifies an effect of a drug on bleeding in CCM lesions. Yet it is unclear at what stage, and for how long a human lesion should be treated to prevent bleeding or rebleeding. It may be compelling to consider drug therapy for a lesion that has recently bled and is hence most likely to rebleed in the next 2 to 3 years, 54 ,55 so ROCK inhibition might be conceived as lesion stabilization therapy. Dose escalation in clinical trials may be calibrated using dynamic contrast-enhanced quantitative perfusion on magnetic resonance imaging that can reflect ROCK-induced hyperpermeability in vivo. 26, 56, 57 Another magnetic resonance imaging biomarker, quantitative susceptibility mapping, may be useful in clinical trials, to assess CCM lesional hemorrhage as a therapeutic outcome in humans, 26, [57] [58] [59] as it was herein shown in mice.
Summary
ROCK inhibitor Fasudil, but not simvastatin, blunted CCM lesion development into mature clinically significant forms. Both drugs significantly decreased lesional bleeding, the first such effect ever reported in CCM. These results justify the development of ROCK inhibitors as therapeutic agents for CCM, and the testing of statins, with cautious dose escalation, in humans.
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